{
  "docId": "019de070-301c-70bd-a010-9a413c6f1b9e",
  "docSlug": "98da217852cb2fba9da82ffbc6cfdefe",
  "documentTitle": "Genetron | IPO Presentation Deck | 41 slides",
  "authorId": "genetron",
  "authorName": "Genetron",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 23,
  "pageCount": 41,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "The slide uses a split-layout: left side focuses on clinical study traction, right side focuses on market context and commercialization milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-301c-70bd-a010-9a413c6f1b9e/23",
  "deckHref": "/decks/019de070-301c-70bd-a010-9a413c6f1b9e",
  "deckJsonHref": "/decks/019de070-301c-70bd-a010-9a413c6f1b9e.json",
  "deckAnchorHref": "/decks/019de070-301c-70bd-a010-9a413c6f1b9e#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.06,
        "y": 0.32
      },
      "kind": "list",
      "text": "Multi-center prospective study with a cohort of 4,500 HBsAg+ individuals since early 2019. 2,000+ cases performed so far. Follow-up work finished in one center in around 80% (297 out of 375) cases demonstrated very positive results from preliminary data.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "680436b5-cb75-4f28-8ba9-e359e1923577",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.06,
        "y": 0.63
      },
      "kind": "list",
      "text": "Most of the HCC cases identified by HCCscreen™ are in very early stage (<3cm). The follow up on the rest cases and in other centers is actively ongoing after the pandemics",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be24af19-6679-43a8-8826-c44a9ec552f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.44,
        "x": 0.52,
        "y": 0.5
      },
      "kind": "list",
      "text": "Currently commercializing via LDT: Formed strategic alliance with iKang Healthcare Group, a leading medical examination network in China",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfeb297a-d1c2-437f-89ad-9280ba77f0f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.44,
        "x": 0.52,
        "y": 0.235
      },
      "kind": "list",
      "text": "Huge market for liver cancer in China: 47.6% of global incidents, 119.5 million high risk population, Limitation in traditional methods, Favorable government policies, Market potential of US$7.2 billion opportunity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d3861476-735c-47f9-b642-91d288313b58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.44,
        "x": 0.52,
        "y": 0.65
      },
      "kind": "list",
      "text": "Preparing for IVD registration: Joined 2020 Major National Science and Technology Projects led by the Ministry of Science and Technology: green channel fast-track status for NMPA registration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7bb6339-cccc-43ad-9a6c-120634e96faf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.38,
        "x": 0.08,
        "y": 0.53
      },
      "kind": "metric",
      "text": "92%+ sensitivity, 93%+ specificity, 35%+ PPV",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e8303c2-84c3-4146-b12a-fe3d0071fdde",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.06,
        "y": 0.235
      },
      "kind": "paragraph",
      "text": "Larger study in progress with further improved results",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0dc890a-29bd-47a4-ac54-15f5ea3da52f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.75,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Enhanced results lay a solid foundation for the commercialization of HCCscreen™",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1e3b8a9-eb9c-48ff-b586-af03d89dbd60",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 23,
      "from": 20,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "61b77ce9-0007-412c-946f-5eeb0ac73f80",
      "evidence": "Slides 20-23 discuss the significant cost advantage presented by Genetron's proprietary technologies and recent development",
      "position": 0,
      "objective": "Highlight the benefits of Genetron's proprietary technologies and significant progress on public medical insurance",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 24,
      "from": 21,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "88fc9991-bd55-435a-bdbb-a386748f4ad0",
      "evidence": "Slides 21-24 discuss HCCscreen™ and its exciting clinical data",
      "position": 1,
      "objective": "Highlight the potential of HCCscreen™ as a blockbuster early liver cancer screening test",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}